ABSTRACT
Comparative data on safety and efficacy of new generation drug-eluting stents (DESs) are still lacking, theobjective of this study is to compare the safety and efficacy of commonly used DESs in patients with coronaryartery disease (CAD). Individual data of 146 consecutive patients (119 male and 27 female) stented with differentDESs such as Sirolimus (SESs), Everolimus (EESs), or Zotarolimus (ZESs) eluting stents were randomly collectedfrom various hospitals in South India. Pooled data were retro-prospectively analyzed, the primary end-point ofthis study was determination of major adverse cardiovascular events (MACE) and individual events, which is acomposite of cardiac death, target vessel related myocardial infarction (TV-MI), target lesion revascularization(TLR), target vessel revascularization (TVR), stent thrombosis (ST), and in-stent restenosis (ISR) at the end ofclinical follow-up which was scheduled at 3 months once up to 1 year after angioplasty. Baseline clinical andcardiac characteristics, angiographic and stent procedural characteristics, efficacy and suspected adverse reactionswere compared. Our study results indicate that SESs (a first-generation DES) were found to be non-inferior toEESs and ZESs in reducing risks and remains safe and effective at the end of 1-year clinical follow-up period inCAD patients after angioplasty.
ABSTRACT
Comparative data on safety and efficacy of new generation drug-eluting stents (DESs) are still lacking, theobjective of this study is to compare the safety and efficacy of commonly used DESs in patients with coronaryartery disease (CAD). Individual data of 146 consecutive patients (119 male and 27 female) stented with differentDESs such as Sirolimus (SESs), Everolimus (EESs), or Zotarolimus (ZESs) eluting stents were randomly collectedfrom various hospitals in South India. Pooled data were retro-prospectively analyzed, the primary end-point ofthis study was determination of major adverse cardiovascular events (MACE) and individual events, which is acomposite of cardiac death, target vessel related myocardial infarction (TV-MI), target lesion revascularization(TLR), target vessel revascularization (TVR), stent thrombosis (ST), and in-stent restenosis (ISR) at the end ofclinical follow-up which was scheduled at 3 months once up to 1 year after angioplasty. Baseline clinical andcardiac characteristics, angiographic and stent procedural characteristics, efficacy and suspected adverse reactionswere compared. Our study results indicate that SESs (a first-generation DES) were found to be non-inferior toEESs and ZESs in reducing risks and remains safe and effective at the end of 1-year clinical follow-up period inCAD patients after angioplasty